- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Ongoing
Phase
II
Principal Investigator(s)
Supachai Rerks-Ngarm, MD
Objective
To assess safety and tolerability of late boost regimens of AIDSVAX B/E alone, ALVAC-HIV alone, or ALVAC-HIV/AIDSVAX B/E combination in HIV-uninfected participants from RV 144.
Prevention Option(s)
HIV Vaccine
Study Design
Controlled
Placebo
Randomized
Double-blind
Arms and Assigned Interventions
Description
ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
Products
AIDSVAX
ALVAC
ARMs
Experimental
Clade
B
E
Description
AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
Products
AIDSVAX
ARMs
Experimental
Clade
B
E
Description
ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
Products
ALVAC
ARMs
Experimental
Official Code
Trial Sponsors
US Army Medical Research and Materiel Command; National Institutes of Health (NIH)
April 2012
May 2017
Enrollment
162
18
Years
Population
Women
Men
Sites
Bang Lamung District Hospital
Chon Buri
Thailand
Phan Thong District Hospital
Chon Buri
Thailand